Mercury Systems Inc (NASDAQ: MRCY) has reported a loss for its first fiscal quarter (ending September 30) of $-0.64 versus a loss $-0.26 for the same period a year ago. This result fell short of […]
For its third fiscal quarter (ending September 30), National Research Corp (NASDAQ: NRC) has reported a -6% decline in E.P.S. from $0.34 a year ago to $0.32 in the current quarter. E.P.S. were $1.17 for […]
The Hain Celestial Group Inc (NASDAQ: HAIN) has reported a loss for its first fiscal quarter (ending September 30) of $-0.12 versus $0.08 for the same period a year ago — a decline of -250%. […]
On 11/7/23, Axogen Inc (NASDAQ: AXGN) stock enjoyed a major increase of 36.9%, closing at $5.38. Relative to the market the stock has been extremely weak over the last nine months but has risen 42.3% […]
TripAdvisor Inc (NASDAQ: TRIP) stock closed at $17.88 on 11/7/23 after a major increase of 11.0%. The stock has risen 23.5% during the last week but has been weak relative to the market over the […]
For its third fiscal quarter (ending September 30), Sage Therapeutics Inc (NASDAQ: SAGE) has reported E.P.S. of $-3.37 compared to $-2.31 a year ago. Relative to the consensus estimate of $-2.69, this was a shortfall […]
Masimo Corp (NASDAQ: MASI) has reported earnings for its third fiscal quarter (ending September 30) of $0.20 versus $0.72 for the same period a year ago — a decline of -72%. Relative to the consensus […]
On 11/7/23, MacroGenics Inc (NASDAQ: MGNX) stock enjoyed a major increase of 17.1%, closing at $6.37. The stock has risen 23.4% during the last week but has been weak relative to the market over the […]
On 11/7/23, Neogenomics Inc (NASDAQ: NEO) stock enjoyed a major increase of 14.2%, closing at $16.73. Relative to the market the stock has been weak over the last nine months but has risen 22.9% during […]
Novanta Inc (NASDAQ: NOVT) has reported E.P.S. of $0.59 for its third fiscal quarter (ending September 30) versus $0.63 for the same period a year ago — a decline of -6%. This performance was $-0.15 […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research